Patents by Inventor Jay D. Albright

Jay D. Albright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
    Patent number: 6946473
    Abstract: Compounds of the formula which are useful in disease conditions mediated by TNF-?, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: September 20, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy I. Levin, James M. Chen, Xue-Mei Du, Jay D. Albright, Arie Zask
  • Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
    Publication number: 20030208066
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: March 17, 2003
    Publication date: November 6, 2003
    Applicant: American Cyanamid Company
    Inventors: Jeremy I.. Levin, James Ming Chen, Xue-Mei Du, Jay D. Albright, Arie Zask
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
    Patent number: 6548524
    Abstract: This invention provides, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-&agr; converting enzyme (TACE. tumor necrosis factor-&agr; converting enzyme) which arc useful for the treatment of diseases in which these enzymes are implicated.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: April 15, 2003
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Patent number: 6534491
    Abstract: This invention provides, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stroinelysins and collagenases) and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr;converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: March 18, 2003
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Tricyclic vasopressin agonists
    Patent number: 6511974
    Abstract: This invention relates to new compounds selected from those of the general formula (I), or a pharmaceutically acceptable salt, ester or prodrug form thereof: wherein D, E and G are N or CH, which serve as vasopressin agonists and are useful in treating disorders such as diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, and the inability to temporarily delay urination and pharmaceutical compositions and methods for same.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: January 28, 2003
    Assignee: Wyeth
    Inventors: John P. Dusza, Peter S. Chan, Jay D. Albright, Jehan F. Bagli, Amedeo A. Failli, Mark A. Ashwell, Albert J. Molinari, Thomas J. Caggiano, Eugene J. Trybulski
  • N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and, methods related thereto
    Publication number: 20020198221
    Abstract: N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide, and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Compositions containing N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide, as well as pharmaceutically acceptable salts thereof, are also disclosed.
    Type: Application
    Filed: December 21, 2001
    Publication date: December 26, 2002
    Applicant: American Cyanamid Company
    Inventors: John P. Dusza, Andrew S. Tomcufcik, Jay D. Albright, Bernard Beer
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Patent number: 6498167
    Abstract: This invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula (B) as shown herein or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: December 24, 2002
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Publication number: 20020132826
    Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula:
    Type: Application
    Filed: December 11, 2000
    Publication date: September 19, 2002
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-&agr;]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
    Patent number: 6399621
    Abstract: N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide, and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Compositions containing N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide, as well as pharmaceutically acceptable salts thereof, are also disclosed.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: June 4, 2002
    Assignee: American Cyanamid Company
    Inventors: John P. Dusza, Andrew S. Tomcufcik, Jay D. Albright, Bernard Beer
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
    Publication number: 20010046989
    Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula:
    Type: Application
    Filed: December 11, 2000
    Publication date: November 29, 2001
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Publication number: 20010025047
    Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula:
    Type: Application
    Filed: December 11, 2000
    Publication date: September 27, 2001
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
    Patent number: 6228869
    Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is P and Q are provided that when P is Q is and vice versa; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 14, 1998
    Date of Patent: May 8, 2001
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Arie Zask, Yansong Gu, Jay D. Albright, Xuemei Du
  • 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
    Patent number: 6071903
    Abstract: Compounds are provided having the following formula: ##STR1## wherein R, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are defined in the specification, which have matrix metalloproteinase inhibiting activity.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: June 6, 2000
    Assignee: American Cyanamid Company
    Inventors: Jay D. Albright, Efren G. Delos Santos, Xuemei Du
  • Tricyclic benzazepine vasopressin antagonists
    Patent number: 5849735
    Abstract: Tricyclic compound of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.
    Type: Grant
    Filed: December 22, 1995
    Date of Patent: December 15, 1998
    Assignee: American Cyanamid Company
    Inventors: Jay D. Albright, Aranapakam M. Venkatesan, Efren G. Delos Santos
  • Tricyclic benzazepine vasopressin antagonists
    Patent number: 5780471
    Abstract: Tricyclic diazepines of the Formula I: ##STR1## wherein A, B, D, E, F, Y, and Z are defined in the specification which compounds have vasopressin and oxytocin antagonist activity.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: July 14, 1998
    Assignee: American Cyanamid Company
    Inventors: Aranapakam M. Venkatesan, Jay D. Albright, George T. Grosu
  • Tricyclic benzazepine vasopressin antagonists
    Patent number: 5719278
    Abstract: Tricyclic compound of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.
    Type: Grant
    Filed: May 31, 1996
    Date of Patent: February 17, 1998
    Assignee: American Cyanamid Company
    Inventors: Jay D. Albright, Efren G. Delos Santos, Xuemei Du, Marvin F. Reich
  • Fused heterocyclic azepines as vasopressin antagonists
    Patent number: 5696112
    Abstract: This invention relates to bicyclic non-peptide vasopressin antagonists useful in treating conditions where decreased vasopressin levels are desired, in conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction, the compounds of this invention having the core structure of ##STR1## wherein: E--Y is selected from the moieties --CH.dbd.CH--, --CH.sub.2 CH.sub.2 --, and ##STR2## the moiety ##STR3## includes an optionally substituted, fused 6-membered heterocyclic aromatic ring containing two nitrogen atoms, a fused 5-membered heterocyclic aromatic ring containing either a) one heteroatom selected from O, S or N; b) two N atoms; or one N atom and one O or S atom;and R.sup.1, R.sup.2, R.sup.3 and R.sub.b are as defined herein.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: December 9, 1997
    Assignee: American Cyanamid Company
    Inventors: Jay D. Albright, Efren G. Delos Santos
  • Tricyclic thieno-azepine vasopressin antagonists
    Patent number: 5654297
    Abstract: This invention relates to new bicyclic non-peptide vasopressin antagonists which are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: August 5, 1997
    Assignee: American Cyanamid Company
    Inventors: Jay D. Albright, Efren G. Delos Santos
  • Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
    Patent number: 5624923
    Abstract: Tricyclic diazepines of the formula: ##STR1## wherein A, B, D, E, F, Y and Z are defined in the specification which compounds have vasopressin and oxytocin antagonist activity.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 29, 1997
    Assignee: American Cyanamid Company
    Inventors: Jay D. Albright, Marvin F. Reich, Fuk-Wah Sum, Efren G. Delos Santos
  • Tricyclic benzazepine vasopressin antagonists
    Patent number: 5612334
    Abstract: Tricyclic compound of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: March 18, 1997
    Assignee: American Cyanamid Company
    Inventors: Jay D. Albright, John P. Dusza